PBR Nachrichten

 

The partnership targets membrane proteins, intracellular protein–protein interactions and complex receptor systems through a new drug discovery platform. It aims to target disease areas where conventional small-molecule drug The post PRISM BioLab partners with Receptor.AI for molecule discovery appeared first on Pharmaceutical Business review....

The partnership aims to investigate ways to implement quantum computing solutions throughout the healthcare value chain, with a focus on resource allocation, research and development, and patient outcomes The post PsiQuantum and National Cancer Center Japan partner on quantum computing appeared first on Pharmaceutical Business review....

The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low- The post Bavarian Nordic and SII sign agreement for chikungunya vaccine production appeared first on Pharmaceutical Business review....

Neupharma will gain exclusive rights for the development and commercialisation of the therapy, addressing a condition currently lacking approved targeted treatments. The company will fund and conduct a The post Curatis and Neupharma sign development agreement for corticorelin in Japan appeared first on Pharmaceutical Business review....

As part of the agreement, Idorsia will receive an upfront payment and retain marketing authorisations in each country. Following local regulatory approval, the company will supply the finished The post Idorsia and Pharmalink sign agreement to distribute Quviviq appeared first on Pharmaceutical Business review....

The approval marks the first authorised treatment for cerebral folate deficiency, a rare genetic neurological disorder affecting brain folate transport. It followed a systematic review of published literature, The post FDA approves GSK's Wellcovorin for cerebral folate deficiency appeared first on Pharmaceutical Business review....

This marks the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage. JS001sc is independently developed by Junshi Biosciences as a subcutaneous The post Junshi receives China's NMPA acceptance for toripalimab injection appeared first on Pharmaceutical Business review....

The collaboration will integrate NewcelX's NCEL-101 with Eledon's investigational anti-cluster of differentiation 40 ligand (anti-CD40L) monoclonal antibody, tegoprubart (AT-1501), to support durable, immune-protected islet replacement and develop a The post NewcelX and Eledon partner for NCEL-101 programme appeared first on Pharmaceutical Business review....

Ecnoglutide is a cyclic adenosine monophosphate (cAMP)-biased glucagon-like peptide-1 (GLP-1) receptor agonist intended for chronic weight management in Chinese adults with obesity or who are overweight. It is The post Sciwind secures China's NMPA approval for Ecnoglutide injection appeared first on Pharmaceutical Business review....

This marks the first FDA approval of a TYK2 inhibitor specifically for this indication. The regulator granted this approval following findings from the pivotal POETYK PsA-I and POETYK The post BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment appeared first on Pharmaceutical Business review....

This approval applies to patients who have undergone at least one prior treatment, including a proteasome inhibitor and an immunomodulatory agent. It aims to provide a new standard The post J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma appeared first on Pharmaceutical Business review....

The licences sourced from Carisma Therapeutics and the University of Pennsylvania include methods and constructs specifically engineered for function within these immune cell populations. The designs complement Liberate Bio's The post Liberate Bio gains licences for myeloid-specific CAR design patents appeared first on Pharmaceutical Business review....

CordenPharma Colorado will occupy the entire premises under a 15-year lease. The new LEED Gold-certified facility has flexible laboratory configurations, advanced mechanical and utility systems, and waste management The post CordenPharma leases space at Flatiron Park for peptides development appeared first on Pharmaceutical Business review....

AFTX-201 is being evaluated as a one-time intravenous gene therapy in adults with genetically confirmed BAG3 DCM. The therapy delivers a fully human, full-length BAG3 transgene using the The post Affinia receives FDA fast track designation for AFTX-201 appeared first on Pharmaceutical Business review....

Alprazolam is the active pharmaceutical ingredient (API) in Xanax, a commonly prescribed anti-anxiety medication. Traditional oral alprazolam tablets can require 25 minutes or more to take effect, as The post Aspire Biopharma and Microsize collaborate for alprazolam powder formulation appeared first on Pharmaceutical Business review....

Enbumyst is approved by the US Food and Drug Administration (FDA) for treating oedema linked to congestive heart failure, hepatic, and renal diseases in adults. The agreement will The post Esperion to acquire Corstasis for cardiovascular franchise expansion appeared first on Pharmaceutical Business review....

Following completion, the combined entity will operate as Candid Therapeutics and list on Nasdaq under the “CDRX” ticker symbol. As part of the merger, Candid has secured more The post Rallybio to acquire Candid Therapeutics appeared first on Pharmaceutical Business review....

CL-273 is a reversible, investigational, wild-type-sparing pan epidermal growth factor receptor (EGFR) small molecule inhibitor developed using an AI-based drug discovery platform. The asset specifically targets resistant mutations The post Kairos Pharma signs deal for Celyn Therapeutics' CL-273 appeared first on Pharmaceutical Business review....

The recommendation applies to children aged two to 11 years experiencing moderate-to-severe CSU who do not respond adequately to histamine-1 antihistamines and are naïve to anti-immunoglobulin E (IgE) therapy. The post Sanofi receives CHMP recommendation for Dupixent approval in Europe appeared first on Pharmaceutical Business review....

This makes Palynziq the only enzyme substitution therapy that received approval to reduce blood phenylalanine (Phe) concentrations in individuals with PKU. The approval follows data from PEGASUS, a The post BioMarin receives FDA approval for Palynziq use in adolescents appeared first on Pharmaceutical Business review....